Catalyst Pharmaceuticals to License North American Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals
June 20, 2023 06:00 ET
|
Catalyst Pharmaceuticals, Inc.
Vamorolone is Currently Under Review with the FDA (PDUFA Date of October 26, 2023) for the Treatment of Duchenne Muscular Dystrophy, a Rare Neuromuscular Disease FDA has Granted Fast Track and Orphan...
CureDuchenne, Muscular Dystrophy Association, and Parent Project Muscular Dystrophy Announce Collaborative Project to Focus on Re-Dosing Gene Therapy in Duchenne Muscular Dystrophy
June 15, 2023 14:43 ET
|
Muscular Dystrophy Association
New York, June 15, 2023 (GLOBE NEWSWIRE) -- June 15, 2023 -- CureDuchenne, Muscular Dystrophy Association (MDA), and Parent Project Muscular Dystrophy (PPMD), today announced a collaborative...
Muscular Dystrophy Association Announces Gene Therapy Support Network for Families Living with Neuromuscular Disease
May 22, 2023 14:48 ET
|
Muscular Dystrophy Association
New York, May 22, 2023 (GLOBE NEWSWIRE) -- Muscular Dystrophy Association (MDA) announced today the launch of the MDA Gene Therapy Support Network (GTx), ahead of a pending FDA approval for the...
Duchenne Muscular Dystrophy Market to Hit Sales of $1533.72 Million by 2028 | DMD Affects 250,000 Children Each Year | Gene Therapy is the Only effective Way to Treat DMD
September 28, 2022 10:22 ET
|
SkyQuest Technology Consulting Pvt. Ltd.
Westford,USA, Sept. 28, 2022 (GLOBE NEWSWIRE) -- There is an increasing demand for Duchenne muscular dystrophy (DMD) therapies, as the condition is still not curable. In the medical industry, there...
Summit Therapeutics Selected for Emerging Science Presentation at the 2018 American Academy of Neurology Annual Meeting
March 28, 2018 07:00 ET
|
Summit Therapeutics plc
OXFORD, United Kingdom and CAMBRIDGE, Mass., March 28, 2018 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM) announces that it has been selected for an Emerging Science dual oral...
Summit Expands Enrolment in PhaseOut DMD Phase 2 Clinical Trial to Include Planned Additional Group
March 07, 2018 07:00 ET
|
Summit Therapeutics plc
Additional Group is Open to Patients Who Participated in Phase 1 Clinical Trials of EzutromidAllows Summit to Gather Additional Safety and Efficacy Data from a Broader Patient Population OXFORD,...
Ezutromid Significantly Reduced Muscle Damage in DMD Patients in 24-Week Interim Data From Summit’s PhaseOut DMD Clinical Trial
January 25, 2018 07:00 ET
|
Summit Therapeutics plc
Increase in Utrophin Protein Expression ObservedSummit Accelerating Preparations for Pivotal Clinical TrialEzutromid is a Potential Disease-Modifying Treatment for the Entire DMD Patient...
Summit Highlights Utrophin Modulation as a Potential Universal Treatment Option in DMD at 15th Action Duchenne International Conference
November 09, 2017 07:00 ET
|
Summit Therapeutics plc
New Preclinical Data Show Utrophin’s Positive Effect on Mitochondria Improving Muscle Health in DMD Model OXFORD, United Kingdom, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc...
Summit Joins cTAP in Collaborative Effort to Enhance the Development of Utrophin Modulators and Other Treatments for Duchenne Muscular Dystrophy
September 25, 2017 07:00 ET
|
Summit Therapeutics PLC
OXFORD, United Kingdom, Sept. 25, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT)(AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...
Summit Presents Data From Phase 1 Clinical Programme of Ezutromid at the European Paediatric Neurology Society Congress
June 22, 2017 07:00 ET
|
Summit Therapeutics PLC
OXFORD, United Kingdom, June 22, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...